Baxter

Baxter International, Inc. engages in the provision of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies, premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software, and services. It operates through the following segment: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Baxter reports robust Q4 sales, eyes growth amid operational challenges

Baxter International's Q4 2022 performance reflects strong sales growth and strategic actions to enhance agility and market responsiveness.
While facing challenges such as lower-than-expected earnings and supply chain constraints, the company is focused on cost reduction and operational improvements.
Opportunities lie in R&D investments, cost synergies from the Hillrom integration, and improving backlog and backorders, positioning Baxter for future growth.
Analysts' concerns about operating margins and financial outlook for 2023 highlight the need for continued efficiency measures and strategic planning.

Baxter beats Q1 expectations, plans spin-off for strategic clarity

Baxter's Q1 performance exceeded expectations with sales growth in key segments and adjusted EPS surpassing guidance.
The company is progressing well with its strategic initiatives, including the spin-off of Renal Care and new operating model.
Challenges in legacy businesses and soft hospital spending highlight areas for improvement, while opportunities lie in new product launches and margin enhancement strategies.
Overall, Baxter's focus on innovation, operational efficiency, and market trends positions it for long-term success and growth.

Baxter exceeds Q2 expectations, eyes growth amid strategic actions

Baxter's Q2 2023 performance showcased resilience and adaptability in a dynamic healthcare market, with strategic actions underway to drive operational efficiency and growth.
The company's focus on innovation, safety, and market responsiveness positions it well for future success, despite challenges such as pending divestitures and market uncertainties.
With a strong performance, growth opportunities in key segments, and operational improvements driving margin expansion, Baxter is navigating challenges to capitalize on future growth prospects.

Baxter beats Q3 expectations, eyes growth through strategic initiatives

Baxter's Q3 2023 performance exceeded expectations, with a focus on strategic priorities and the upcoming Kidney Care segment separation.
The company's strengths lie in maintaining market share, operational efficiencies, and maximizing shareholder value through financial analysis.
Challenges include renegotiating contracts, rising energy costs, and achieving organic growth amidst market dynamics.
Opportunities for Baxter include growth through cost improvements, margin programs, and product launches in 2024.

Baxter surpasses Q4 expectations, eyes growth amid inflation challenges

Baxter's Q4 2023 performance exceeded expectations, driven by growth in key segments and strategic initiatives, setting the stage for continued success in 2024.
Despite challenges like inflation and flat growth in certain segments, Baxter's focus on margin improvement, debt management, and growth strategies positions the company for future resilience.
With a strong outlook for 2024, Baxter aims to capitalize on opportunities for growth, margin improvement, and market expansion, supported by a solid financial foundation and strategic priorities.

Baxter surpasses Q1 expectations with focus on innovation and growth

Baxter's Q1 2024 performance exceeded expectations, driven by strong sales growth and focus on innovation, despite challenges in certain segments and geographies.
The company's strategic strengths lie in diverse growth drivers, strong segment margins, and geographic expansion successes, positioning it for continued success.
Addressing challenges in underperforming segments and markets, along with seizing opportunities for improvement and expansion, will be crucial for Baxter's future growth.
With a clear focus on innovation, margin expansion, and shareholder value maximization, Baxter aims to navigate challenges and capitalize on growth prospects for sustained success.

Baxter exceeds Q2 expectations, plans Kidney Care separation for growth

Baxter International's Q2 2024 earnings call highlighted robust performance, strategic initiatives, and a positive outlook for sales growth and earnings per share.
The company's focus on margin improvement, innovation, and operational efficiency positions it well for sustained growth and shareholder value creation.
While facing challenges in certain segments and external factors, Baxter's proactive approach and strong fundamentals offer opportunities for future expansion and success.
Investors can look forward to Baxter's continued commitment to driving growth, expanding margins, and delivering innovative healthcare solutions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Baxter's (BAX) second-quarter 2023 results reflect sustained demand for its medically essential products amid a stabilizing macroeconomic climate and healthcare marketplace.

Baxter (BAX) Beats on Q2 Earnings, Revises 2023 EPS Guidance

Baxter International beat Wall Street expectations for second-quarter sales, helped by higher demand for its medical devices.

Baxter beats sales estimates on strong demand for medical devices

Although the revenue and EPS for Baxter (BAX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Baxter (BAX) Reports Q2 Earnings: What Key Metrics Have to Say

Baxter International (BAX) came out with quarterly earnings of $0.55 per share, missing the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.87 per share a year ago.

Baxter International (BAX) Lags Q2 Earnings and Revenue Estimates

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2023. “Baxter's second-quarter performance reflects ongoing solid demand for our diverse, durable portfolio of medically essential products,” said José (Joe) E. Almeida, chairman, president and chief executive officer. “We are making progress across the transformational actions we announced at the start of 2023. These initiatives are focused on enhanc.

Baxter Reports Second-Quarter 2023 Results

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 11, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) securities between May 25, 2022 and February 8, 2023, inclusive (the “Class Period”). If you suffered a loss on your Baxter investments or would like to inquire about potentially pursu.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Baxter International Inc. (BAX)

LOS ANGELES, CA / ACCESSWIRE / July 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. ("Baxter" or "the Company") (NYSE:BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 25, 2022 and February 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 11, 2023.

INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Baxter International Inc. with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)---- $BAX #BAX--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Baxter International Inc. (NYSE: BAX) between May 12, 2022 and February 8, 2023, both dates inclusive (the “Class Period”), of the important September 11, 2023 lead plaintiff deadline. SO WHAT: If you purchased Baxter securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. W.

BAX INVESTOR NEWS: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Baxter International Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BAX

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming September 11, 2023 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) securities between May 25, 2022 and February 8, 2023, inclusive (the “Class Period”). Investors suffering losses on their Baxter investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their le.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Baxter International Inc. (BAX)

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that Vantive will be the name of the company's proposed spinoff of its Renal Care and Acute Therapies businesses. Vantive is expected to launch as an independent, publicly traded company by July 2024 or earlier, subject to satisfaction of customary conditions. “Announcing the Vantive name is a critical milestone in our journey to becoming an independent company focused solely on ther.

Baxter Announces Vantive as the Name of Proposed Kidney Care Spinoff

LOS ANGELES, CA / ACCESSWIRE / July 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. ("Baxter" or "the Company") (NYSE:BAX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 25, 2022 and February 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 11, 2023.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Baxter International Inc. with Losses of $500,000 to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)---- $BAX #BAX--Baxter International, Inc. (BAX) Misled Investors Regarding the Impact of its Supply Chain Problems.

Baxter International, Inc. (BAX) Class Action Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Baxter International, Inc. Securities Class Action

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) securities between May 25, 2022 and February 8, 2023, inclusive (the “Class Period”). Baxter investors have until September 11, 2023 to file a lead plaintiff motion. If you suffered a loss on your Baxte.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Baxter International Inc. (BAX) Investors

NEW YORK , July 24, 2023 /PRNewswire/ -- Bernstein Liebhard LLP: Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Baxter International, Inc. ("Baxter" or the "Company") (NYSE: BAX) between May 25, 2022 and February 8, 2023 , inclusive (the "Class Period"). The lawsuit was filed in the United States District Court for the Northern District of Illinois and alleges violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the "Complaint").

BAXTER INTERNATIONAL, INC. (NYSE: BAX) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Baxter International, Inc.

NEW YORK , July 22, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Baxter International Inc. (NYSE: BAX) between May 12, 2022 and February 8, 2023, both dates inclusive (the "Class Period"), of the important  September 11, 2023 lead plaintiff deadline. SO WHAT: If you purchased Baxter securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Baxter International Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BAX

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) securities between May 25, 2022 and February 8, 2023, inclusive (the “Class Period”). Baxter investors have until September 11, 2023 to file a lead plaintiff motion. Investors suffering losses on their Baxter investments are encouraged to contact the Law Offices of Howard G. Smit.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Baxter International Inc. (BAX) Investors

Baxter's (BAX) second-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.

Baxter (BAX) to Post Q2 Earnings: What's in the Offing?

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 11, 2023 to file lead plaintiff applications in a securities class action lawsuit against Baxter International Inc. (NYSE: BAX), if they purchased the Company's securities between May 12, 2022 and February 8, 2023, inclusive (the “Class Period”). This action is pending in the United States District Court for.

BAXTER SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Baxter International Inc. - BAX

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Baxter International (BAX) Q2 Earnings Expected to Decline

NEW YORK--(BUSINESS WIRE)---- $BAX #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Baxter International Inc. ("Baxter" or “the Company”) (NYSE: BAX) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Baxter.

Calling All Baxter International Inc. (BAX) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses!

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Baxter investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Baxter International Inc. (BAX) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) investors concerning the Company's possible violations of federal securities laws. On February 9, 2023, before the market opened, Baxter released its fourth quarter and full year 2022 financial results, revealing that the Company did not meet its earning guidance for the year. The Company claimed that “supply chain headwinds con.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Baxter International Inc. (BAX) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On February 9, 2023, before the market opened, Baxter released its fourth quarter and full year 2022 financial results, revealing that the Company did not meet its earning.

The Law Offices of Frank R. Cruz Announces Investigation of Baxter International Inc. (BAX) on Behalf of Investors

LOS ANGELES, CA / ACCESSWIRE / July 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. ("Baxter" or "the Company") (NYSE:BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 25, 2022 and February 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 11, 2023.

INVESTOR DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Baxter International Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. ("Baxter" or "the Company") (NYSE:BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 25, 2022 and February 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 11, 2023.

News for Baxter Stock (BAX)